Managing AML is pleased to present this complimentary CME/CPE/CNE webinar
Live Interactive Webcast Series
In order to successfully develop targeted treatment plans and meet the clinical and disease needs of individual patients with AML, one must understand the key safety and efficacy data. This activity will focus on practical expert recommendations for optimizing the use of new and recently approved agents and regimens. Hear from three experts as they review the most appropriate therapeutic strategies for individual patients. You may submit questions about your practice and hear the experts respond during the live Q&A segment at the end of their presentation.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Apply updated recommendations for diagnostic and prognostic evaluation of acute myeloid leukemia (AML) in clinical practice, including optimal use of molecular testing
- Incorporate new and emerging therapies into the treatment paradigm to provide optimal care for patients with newly diagnosed or relapsed/refractory AML
- Develop individualized treatment plans for patients with AML based on age, risk assessment, and other patient- or disease-related factors
- Identify active clinical trials in both newly diagnosed and relapsed/refractory AML and incorporate referral to these trials when appropriate into treatment plans
Naval Daver, MD - Moderator
Director, Leukemia Research Alliance Program
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Jessica Altman, MD
Robert H. Lurie Comprehensive Cancer Center
Alexander Perl, MD
Associate Professor of Medicine
Abramson Cancer Center
University of Pennsylvania
|15 minutes||Frontline Treatment in AML: What You Need to Know to Choose the Best Option for Your Patient – Dr. Alexander Perl|
|15 minutes||Treating Relapsed/Refractory AML: How to Choose the Right Options – Dr. Jessica Altman|
|15 minutes||What's Next: New Data and Clinical Trials That Could Change Treatment – Dr. Naval Daver|
|15 minutes||Audience Q&A|
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-20-024-L01-P . Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 20-024-122
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Naval Daver has received honoraria related to formal advisory activities and as a consultant from AbbVie Inc., Agios, Astellas Pharma US, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo, Inc., ImmunoGen, Inc., Incyte Corporation, Jazz Pharmaceuticals plc, Karyopharm Therapeutics, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., and Sunesis. He has received grant support related to research activities from AbbVie, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Inc., GlycoMimetics, Inc., ImmunoGen, Incyte, Karyopharm, Nohla Therapeutics, Novartis, Pfizer, SERVIER, and Sunesis.
Dr. Jessica Altman has received honoraria related to formal advisory activities from AbbVie Inc., Agios, Daiichi Sankyo, Inc., and Theradex Systems, Inc., as well as speakers’ bureau activities from the France Foundation. She has also disclosed a financial relationship with GlycoMimetics, Inc. (Data Safety and Monitoring Committee).
Dr. Alexander Perl has received honoraria as a consultant from AbbVie Inc., Actinium Pharmaceuticals, Inc., Arog Pharmaceuticals, Inc., Astellas Pharma US, Inc., Daiichi Sankyo, Inc., FORMA Therapeutics, Inc., and the Leukemia and Lymphoma Society, as well as formal advisory activities from Loxo Oncology and NewLink Genetics Corporation. He has received grant support related to research activities from AbbVie, Astellas, Bayer AG, Daiichi Sankyo, and Novartis AG.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Wilma Guerra, Program Director, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Americans with Disabilities Act/Special Needs
MediCom Worldwide, Inc. is committed to equality of educational opportunity and does not discriminate against applicants, students, or employees on the basis of race, color, religion, sex, national origin, age, disability, veterans status, or sexual orientation.
Instructions for Participation and Credit
There are no fees for participating in this activity.
In order to receive credit, all participants must complete the self-assessment post-test and Activity Evaluation following the activity. Partial credit will not be awarded for this activity.
CME and CNE Credit certificates will be emailed 4 weeks following receipt of completed requirements.
CPE Credit will be awarded upon completion of a self-assessment and evaluation. Participation verification must be completed within 4 weeks of the activity. Your online CPE certificate will be reported directly to CPE Monitor within 4 weeks of receiving post-activity documentation.
If you have any questions, please contact MediCom Worldwide, Inc. at 800-408-4242, ext. 110 or firstname.lastname@example.org.
A confirmation screen will appear after your information is submitted. You will also receive an email registration confirmation within two business days.
If you do not receive the confirmation email, please check your spam or junk folder. You may also need to check with your network administrator.
Please complete the form below. Mandatory information is asterisked*.
Supported by educational grants from Celgene Corporation, Helsinn, and Pfizer, Inc.